William Blair analyst Sami Corwin initiated coverage of Kyverna Therapeutics (KYTX) with an Outperform rating and $27 fair value estimate. Kyverna is a clinical-stage biotechnology company developing immune cell therapies that can induce long-term remissions for patients with severe autoimmune diseases without the need for chronic immunosuppression, the analyst tells investors in a research note. The firm believes the company is on track have the first FDA approved CAR-T for the treatment of an autoimmune disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics: Promising Potential in Immune Cell Therapies with KYV-101
- Kyverna Therapeutics: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
- Kyverna Therapeutics: Attractive Risk-Reward Profile with Upcoming Catalysts and Discounted Valuation
- Kyverna Therapeutics Advances CAR T-Cell Therapy Trials
- Kyverna Therapeutics: Promising Advancements in Neuroimmunology and Strategic Positioning for Market Leadership